Download PDF
Semin Respir Crit Care Med 2009; 30(2): 127-135
DOI: 10.1055/s-0029-1202941
© Thieme Medical Publishers

Global and Local Epidemiology of Community-Acquired Pneumonia: The Experience of the CAPNETZ Network

Tobias Welte1 , Thomas Köhnlein1
  • 1Department of Pulmonary Medicine, Medizinische Hochschule Hannover, Hannover, Germany
Further Information

Publication History

Publication Date:
18 March 2009 (online)

    Permissions and Reprints

ABSTRACT

Community-acquired pneumonia (CAP) is a major cause of morbidity and mortality worldwide. Young children and the elderly are disproportionately affected by CAP. Lower respiratory tract infections (LRTIs), including CAP, were ranked third in a list of the 30 leading causes of death worldwide in 1990. Mortality rates are low (< 2%) in CAP patients treated as outpatients, but are higher (5 to 20%) among patients hospitalized for CAP, and are highest (up to 50%) in patients admitted to the intensive care unit. Several risk factors are known to be associated with increases in mortality, the most important of which are age > 65 years, male gender, and comorbidities such as chronic heart failure, advanced chronic obstructive pulmonary disease, neurological diseases, and liver cirrhosis. Patients living in nursing homes may have a special risk for multiresistant bacterial infection. The incidence of CAP varies worldwide by country, age, and gender. Further, data about epidemiology, etiology, morbidity, mortality, and economical burden of diseases differ between countries. In this review, we present recent data regarding the incidence, etiology, and rate of antibiotic resistance among CAP patients from the German Network for Community Acquired Pneumonia (CAPNETZ) registry and review data from several European countries.

KEYWORDS

Community-acquired pneumonia - Europe - incidence - lower respiratory tract infections

REFERENCES

  • 1 Murray C JL, Lopez A D. Mortality by cause for eight regions of the world: Global Burden of Disease Study.  Lancet. 1997;  349 1269-1276
    CrossrefPubMedSearch in Google Scholar
  • 2 Bundesgeschäftsstelle für Qualitätssicherung . Qualitätsreport BQS 2007 Hrg.  Düsseldorf. 2008;  28-34
    PubMedSearch in Google Scholar
  • 3 Welte T, Suttorp N, Marre R. CAPNETZ–community-acquired pneumonia competence network.  Infection. 2004;  32 234-238
    PubMedSearch in Google Scholar
  • 4 Trotter C L, Stuart J M, George R, Miller E. Increasing hospital admissions for pneumonia, England.  Emerg Infect Dis. 2008;  14 727-733
    CrossrefPubMedSearch in Google Scholar
  • 5 European Respiratory Society/European Lung Foundation .Pneumonia. In: European Respiratory Society/European Lung Foundation. European Lung White Book. Sheffield, UK; 2003: 55-65
    Search in Google Scholar
  • 6 Schnoor M, Hedicke J, Dalhoff K, Raspe H, Schafer T. CAPNETZ study group: approaches to estimate the population-based incidence of community acquired pneumonia.  J Infect. 2007;  55 233-239
    CrossrefPubMedSearch in Google Scholar
  • 7 Mandell L A. Spectrum of microbial etiology of community- acquired pneumonia in hospitalized patients: implications for selection of the population for enrollment in clinical trials.  Clin Infect Dis. 2008;  47 S189-S192
    CrossrefPubMedSearch in Google Scholar
  • 8 Marston B J, Plouffe J F, File T M et al.. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group.  Arch Intern Med. 1997;  157 1709-1718
    CrossrefPubMedSearch in Google Scholar
  • 9 Niederman M S, McCombs J S, Unger A N, Kumar A, Popovian R. The cost of treating community-acquired pneumonia.  Clin Ther. 1998;  20 820-837
    CrossrefPubMedSearch in Google Scholar
  • 10 Monge V, San-Martin M, Gonzalez A. The burden of community-acquired pneumonia in Spain.  Eur J Public Health. 2001;  11 362-364
    CrossrefPubMedSearch in Google Scholar
  • 11 United Nations Population Division .World population prospects: the 2006 revision population database. Available at http://esa.un.org/unpp/p2k0data.asp Accessed October 25, 2008
    Search in Google Scholar
  • 12 Bartolome M, Almirall J, Morera J Maresme Community-Acquired Pneumonia Study Group (GEMPAC) et al. A population-based study of the costs of care for community-acquired pneumonia.  Eur Respir J. 2004;  23 610-616
    CrossrefPubMedSearch in Google Scholar
  • 13 Bauer T T, Welte T, Ernen C et al.. Cost analyses of community-acquired pneumonia from the hospital perspective.  Chest. 2005;  128 2238-2246
    CrossrefPubMedSearch in Google Scholar
  • 14 Restrepo M I, Mortensen E M, Valez J A et al.. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU.  Chest. 2008;  133 610-617
    CrossrefPubMedSearch in Google Scholar
  • 15 Welte T, Marre R, Suttorp N. Kompetenznetzwerk “Ambulant Erworbene Pneumonie” (CAPNETZ) . What is new in the treatment of community-acquired pneumonia? [in German].  Med Klin (Munich). 2006;  101 313-320
    CrossrefPubMedSearch in Google Scholar
  • 16 Koivula I, Stén M, Mäkelä P H. Prognosis after community-acquired pneumonia in the elderly: a population-based 12-year follow-up study.  Arch Intern Med. 1999;  159 1550-1555
    CrossrefPubMedSearch in Google Scholar
  • 17 Yende S, D'Angelo G, Kellum J A GenIMS Investigators et al. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis.  Am J Respir Crit Care Med. 2008;  177 1242-1247
    CrossrefPubMedSearch in Google Scholar
  • 18 El Solh A, Pineda L, Bouquin P, Mankowski C. Determinants of short and long term functional recovery after hospitalization for community-acquired pneumonia in the elderly: role of inflammatory markers.  BMC Geriatr. 2006;  6 12
    CrossrefPubMedSearch in Google Scholar
  • 19 Garbino J, Sommer R, Gerber A et al.. Prospective epidemiologic survey of patients with community-acquired pneumonia requiring hospitalization in Switzerland.  Int J Infect Dis. 2002;  6 288-293
    CrossrefPubMedSearch in Google Scholar
  • 20 Giorgi Rossi P, Agabiti N, Faustini A et al.. The burden of hospitalised pneumonia in Lazio, Italy, 1997–1999.  Int J Tuberc Lung Dis. 2004;  8 528-536
    PubMedSearch in Google Scholar
  • 21 Froes F. Pneumonia in the adult population in continental Portugal: incidence and mortality in hospitalized patients from 1998 to 2000 [in Spanish].  Rev Port Pneumol. 2003;  9 187-194
    PubMedSearch in Google Scholar
  • 22 Falcó V, Almirante B, Jordano Q et al.. Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediately resistant strains?.  J Antimicrob Chemother. 2004;  54 481-488
    CrossrefPubMedSearch in Google Scholar
  • 23 Aspa J, Rajas O, Rodríguez de Castro F Pneumococcal Pneumonia in Spain Study Group et al.. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors.  Clin Infect Dis. 2004;  38 787-798
    CrossrefPubMedSearch in Google Scholar
  • 24 Viegi G, Pistelli R, Cazzola M et al.. Epidemiological survey on incidence and treatment of community acquired pneumonia in Italy.  Respir Med. 2006;  100 46-55
    CrossrefPubMedSearch in Google Scholar
  • 25 Foley S C, Kelly E M, O'Neill S J. Audit of the management of patients admitted with community acquired pneumonia.  Ir Med J. 2006;  99 138-140
    PubMedSearch in Google Scholar
  • 26 Menéndez R, Torres A, Zalacain R Neumofail Group et al.. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome.  Thorax. 2004;  59 960-965
    CrossrefPubMedSearch in Google Scholar
  • 27 Ochoa-Gondar O, Vila-Córcoles A, de Diego C EVAN-65 Study Group et al.. The burden of community-acquired pneumonia in the elderly: the Spanish EVAN-65 study.  BMC Public Health. 2008;  8 222
    CrossrefPubMedSearch in Google Scholar
  • 28 Braun J J, de Graaff C S, de Goey J, Zwinderman A H, Petit P LC. Community-acquired pneumonia: pathogens and course in patients admitted to a general hospital [in Dutch].  Ned Tijdschr Geneeskd. 2004;  148 836-840
    PubMedSearch in Google Scholar
  • 29 Paganin F, Lilienthal F, Bourdin A et al.. Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor.  Eur Respir J. 2004;  24 779-785
    CrossrefPubMedSearch in Google Scholar
  • 30 Rello J, Bodi M, Mariscal D et al.. Microbiological testing and outcome of patients with severe community-acquired pneumonia.  Chest. 2003;  123 174-180
    CrossrefPubMedSearch in Google Scholar
  • 31 Vallès X, Marcos A, Pinart M et al.. Hospitalized community-acquired pneumonia due to Streptococcus pneumoniae: has resistance to antibiotics decreased?.  Chest. 2006;  130 800-806
    CrossrefPubMedSearch in Google Scholar
  • 32 Rosón B, Carratalà J, Fernández-Sabé N, Tubau F, Manresa F, Gudiol F. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia.  Arch Intern Med. 2004;  164 502-508
    CrossrefPubMedSearch in Google Scholar
  • 33 Bonnard P, Lescure F X, Douadi Y et al.. Community-acquired bacteraemic pneumococcal pneumonia in adults: effect of diminished penicillin susceptibility on clinical outcome.  J Infect. 2005;  51 69-76
    CrossrefPubMedSearch in Google Scholar
  • 34 Melegaro A, Edmunds W J, Pebody R, Miller E, George R. The current burden of pneumococcal disease in England and Wales.  J Infect. 2006;  52 37-48
    CrossrefPubMedSearch in Google Scholar
  • 35 Kothe H, Bauer T, Marre R, Suttorp N, Welte T, Dalhoff K. Competence Network for Community-Acquired Pneumonia Study Group . Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment.  Eur Respir J. 2008;  32 139-146
    CrossrefPubMedSearch in Google Scholar
  • 36 Kollef M H, Shorr A, Tabak Y P et al.. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia.  Chest. 2005;  128 3854-3862
    CrossrefPubMedSearch in Google Scholar
  • 37 Echols R M, Tillotson G S, Song J X, Tosiello R L. Clinical trial design for mild-to-moderate community-acquired pneumonia: an industry perspective.  Clin Infect Dis. 2008;  47(Suppl 3) S166-S175
    CrossrefPubMedSearch in Google Scholar
  • 38 Nielsen S V, Poullsen K, Jørgensen L M, Rasmussen E, Sanders S, Henrichsen J. Incidence and diagnosis of cases of pneumonia caused by pneumococci that required hospitalization [in Danish].  Ugeskr Laeger. 1992;  154 412-415
    PubMedSearch in Google Scholar
  • 39 Jokinen C, Heiskanen L, Juvonen H et al.. Microbial etiology of community-acquired pneumonia in the adult population of 4 municipalities in eastern Finland.  Clin Infect Dis. 2001;  32 1141-1154
    CrossrefPubMedSearch in Google Scholar
  • 40 Lim W S, Macfarlane J T, Boswell T CJ et al.. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines.  Thorax. 2001;  56 296-301
    CrossrefPubMedSearch in Google Scholar
  • 41 Welte T. Treatment of hospitalized patients with community-acquired pneumonia: reply [letter].  Clin Infect Dis. 2006;  43 110
    CrossrefPubMedSearch in Google Scholar
  • 42 Beović B, Bonac B, Kese D et al.. Aetiology and clinical presentation of mild community-acquired bacterial pneumonia.  Eur J Clin Microbiol Infect Dis. 2003;  22 584-591
    CrossrefPubMedSearch in Google Scholar
  • 43 Fernandez Alvarez R, Suarez Toste I, Rubinos Cuadrado G et al.. Community-acquired pneumonia: aetiologic changes in a limited geographic area. An 11-year prospective study.  Eur J Clin Microbiol Infect Dis. 2007;  26 495-499
    CrossrefPubMedSearch in Google Scholar
  • 44 Guglielmo L, Leone R. Veneto Pneumonia Research Group . Aetiology and therapy of community-acquired pneumonia: a hospital study in northern Italy.  Eur J Clin Pharmacol. 1997;  51 437-443
    CrossrefPubMedSearch in Google Scholar
  • 45 Ostergaard L, Andersen P L. Etiology of community-acquired pneumonia: evaluation by transtracheal aspiration, blood culture, or serology.  Chest. 1993;  104 1400-1407
    PubMedSearch in Google Scholar
  • 46 Laurichesse H, Sotto A, Bonnet E Infectio-Sud Study Group et al.. Pre- and in-hospital management of community-acquired pneumonia in Southern France, 1998–99.  Eur J Clin Microbiol Infect Dis. 2001;  20 770-778
    CrossrefPubMedSearch in Google Scholar
  • 47 Wellinghausen N, Straube E, Freidank H, von Baum H, Marre R, Essig A. Low prevalence of Chlamydia pneumoniae in adults with community-acquired pneumonia.  Int J Med Microbiol. 2006;  296 485-491
    CrossrefPubMedSearch in Google Scholar
  • 48 von Baum H, Ewig S, Marre R Competence Network for Community Acquired Pneumonia Study Group et al. Community-acquired Legionella pneumonia: new insights from the German competence network for community acquired pneumonia.  Clin Infect Dis. 2008;  46 1356-1364
    CrossrefPubMedSearch in Google Scholar
  • 49 De Roux A, Marcos M A, Garcia E et al.. Viral community-acquired pneumonia in nonimmunocompromised adults.  Chest. 2004;  125 1343-1351
    CrossrefPubMedSearch in Google Scholar
  • 50 Apisarnthanarak A, Mundy L M. Etiology of community-acquired pneumonia.  Clin Chest Med. 2005;  26 47-55
    CrossrefPubMedSearch in Google Scholar
  • 51 Vanderkooi O G, Low D E, Green K, Powis J E, McGeer A. for the Toronto Invasive Bacterial Disease Network . Predicting antimicrobial resistance in invasive pneumococcal infections.  Clin Infect Dis. 2005;  40 1288-1297
    CrossrefPubMedSearch in Google Scholar
  • 52 Yu V L, Chiou C CC, Feldman C International Pneumococcal Study Group et al.. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome.  Clin Infect Dis. 2003;  37 230-237
    CrossrefPubMedSearch in Google Scholar
  • 53 Daneman N, McGeer A, Green K, Low D E. Toronto Invasive Bacterial Diseases Network . Macrolide resistance in bacteremic pneumococcal disease: implications for patient management.  Clin Infect Dis. 2006;  43 432-438
    CrossrefPubMedSearch in Google Scholar
  • 54 Whitney C G, Farley M M, Hadler J et al.. Active bacterial core surveillance of the emerging infections program network: invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine.  N Engl J Med. 2003;  348 1737-1746
    CrossrefPubMedSearch in Google Scholar
  • 55 Stephens D S, Zughaier S M, Whitney C G Georgia Emerging Infections Program et al.. Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment.  Lancet. 2005;  365 855-863
    CrossrefPubMedSearch in Google Scholar
  • 56 Low D E. Quinolone resistance among pneumococci: therapeutic and diagnostic implications.  Clin Infect Dis. 2004;  38(Suppl 4) S357-S362
    CrossrefPubMedSearch in Google Scholar
  • 57 Woodhead M, Blasi F, Ewig S et al.. Guidelines for the management of adult lower respiratory tract infections.  Eur Respir J. 2005;  26 1138-1180
    CrossrefPubMedSearch in Google Scholar

Tobias WelteM.D. 

Department of Pulmonary Medicine, Medizinische Hochschule Hannover

Carl Neuberg Strasse 1, D-30625 Hannover, Germany

Email: welte.tobias@mh-hannover.de